Several molecules have been shown to modulate PD-L1 expression on tumor cells, which can be exploited as monotherapies, combined to other drugs to help potentiate their action or combined to PD-1/PD-L1 inhibitors. This evidence concerns the gene PDCD1 and neoplasm.